Fig. 2.
(A) Rates of clinical remission per partial Mayo score in the effectiveness analysis population (observed cases). Clinical remission was defined by a partial Mayo score ≤2 points with no individual subscore >1 point. (B) Rates of corticosteroid-free remission in patients initiating adalimumab with concomitant corticosteroid therapy (observed cases). (C) Rates of mucosal healing in the effectiveness analysis population (observed cases); mucosal healing was defined as a Mayo endoscopic subscore ≤1.